Today, CDC announced the release of more than 77,000 additional doses of Beyfortus™ (nirsevimab-alip (100 mg), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease.
Contact Us
For questions, or to make an appointment please
call us at 240-622-3007
Washington DC
1418 Good Hope Road SE
Washington, DC 20020
Maryland
9500 Medical Center Drive
Suite 104
Largo, MD 20774
